Polar Asset Management Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Polar Asset Management Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,700	Closed	-$455K	–	833
2023 Q4	$455K	Sell	3,700 -27,800	-88%	-$3.47M	0.01%	472
2023 Q3	$4.08M	Sell	31,500 -5,000	-14%	-$666K	0.09%	267
2023 Q2	$4.52M	Sell	36,500 -185,100	-84%	-$24.9M	0.08%	311
2023 Q1	$32.4M	Buy	221,600 +69,900	+46%	+$10.3M	0.49%	24
2022 Q4	$24.2M	Sell	151,700 -13,900	-8%	-$2.04M	0.3%	51
2022 Q3	$22.1M	Buy	165,600 +3,500	+2%	+$532K	0.26%	65
2022 Q2	$25.3M	Buy	162,100 +2,600	+2%	+$400K	0.29%	60
2022 Q1	$24.8M	Buy	159,500 +55,900	+54%	+$8.11M	0.27%	61
2021 Q4	$13.2M	Buy	103,600 +65,900	+175%	+$8.66M	0.14%	173
2021 Q3	$4.91M	Buy	+37,700	New	+$5.7M	0.05%	396

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Polar Asset Management Partners's JAZZ Position: Q1 2024 in Review

Polar Asset Management Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2024, closing a stake of 3,700 shares — an estimated $455K sold.

Polar Asset Management Partners first reported a position in JAZZ in Q3 2021 and held it in 10 quarters. The position peaked at $32.4M in Q1 2023. 480 funds tracked by Wall St. Rank hold JAZZ as of Q1 2024.

Polar Asset Management Partners reported no remaining Jazz Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Polar Asset Management Partners sold 3,700 Jazz Pharmaceuticals shares in Q1 2024, an estimated $455K.
Polar Asset Management Partners first reported a position in Jazz Pharmaceuticals in Q3 2021 and held it in 10 quarters.
Polar Asset Management Partners's Jazz Pharmaceuticals position peaked at $32.4M in Q1 2023.
480 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2024.

Based on Polar Asset Management Partners's 13F filing for Q1 2024, filed 15 May 2024.